What seems like a straightforward idea—screen current and former heavy smokers for lung cancer—proves more challenging in practice, according to findings from a demonstration project at the Minneapolis Veterans Affairs Health Care System.
CRANBURY, N.J.—Lung cancer screening is free under the Affordable Care Act for certain current and former smokers, after a national study found their risk of cancer death fell 20 percent through annual screening with low-dose computed tomography (LDCT) instead of chest x-rays.
But getting the right people screened in the real world isn’t as simple as it sounds, according to findings in the current issue of The American Journal of Managed Care®. Authors report on a demonstration project among current and former smokers who were screened in the Minneapolis Veterans Affairs Health Care System. Among their findings:
The research sheds light on the challenges of getting the large pool of potentially eligible current and former smokers through the annual screening process. Just 1.9 percent of eligible smokers were screened in 2016, according to data presented in early June at the American Society of Clinical Oncology.
Criteria from the US Preventive Services Task Force call for screening smokers age 55 to 80 who have smoked at least 30 pack-years, or those with that history who have quit within the past 15 years. Thus, the authors note, getting patients screened requires that health systems have the capacity to capture patient information and track down those who meet the criteria. Health systems also must handle patients who may experience anxiety after a nodule is found, even if it is unlikely to become cancerous.
“Important considerations in lung cancer screening are accurate identification of eligible patients, balancing invitation approaches with resource constraints, and establishing standardized methods for tracking numerous small lung nodules and incidental findings detected by LDCT,” the authors conclude.
“Lung cancer screening implementation presents unique challenges, but they are not insurmountable. With more research and experience, we will find the best method to deliver this important cancer screening intervention to the millions of Americans that need it,” said Angela E. Fabbrini, MPH, lead author and director of the lung cancer screen program in the Minneapolis Veterans Administration Health Care System.
About The American Journal of Managed Care®:
The American Journal of Managed Care® (AJMC®) is a peer-reviewed, MEDLINE-indexed journal that keeps readers on the forefront of health policy by publishing research relevant to industry decision makers as they work to promote the efficient delivery of high-quality care. AJMC.com is the essential website for managed care professionals, distributing industry updates daily to leading stakeholders. Other titles in the AJMC® family include The American Journal of Accountable Care®, and two evidence-based series, Evidence-Based Oncology™ and Evidence-Based Diabetes Management™. These comprehensive offerings bring together stakeholder views from payers, providers, policymakers and other industry leaders in managed care. To order reprints of articles appearing in AJMC® publications, please contact Jeff Prescott at 609-716-7777, ext. 331.
Contacts:
AJMC® Media:
Theresa Burek, 609-716-7777
or
Surabhi Verma
Dr Dalia Rotstein: Physicians Must Be Aware MS Affects People of All Backgrounds
April 24th 2024Dalia Rotstein, MD, MPH, emphazises the importance of awareness that multiple sclerosis (MS) impacts patients from various backgrounds as clinicians think through ways to improve access to care and research efforts in MS.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Award-Winning Poster Presentations From AMCP 2024
April 23rd 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, multiple poster presentations concerned with health equity, data collection, glucagon-like peptide-1 agonists, and more were acknowledged for their originality, relevance, clarity, bias, and quality.
Read More